Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 298

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 298
---
. Under the terms of the Benuvia License Agreement, Benuvia will be responsible for the manufacturing and supply of the Spray Formulations, but Channel will have exclusive, worldwide rights to develop, commercialize and distribute the Spray Formulations. Channel currently does not have strategy and development plans for the Spray Formulations licensed from Benuvia. Channel’s Strategy Channel is a clinical-stage pharmaceutical company focused on non-opioid pain blockers in the NaV space. Its development programs are initially designed to address the underlying condition and mitigate the pain associated with neuropathic pain and eye pain. The key elements of its strategy to achieve its mission are:

| • | Develop CT2000 for the treatment of eye pain.According to a presentation at the Association for Research in Vision and Ophthalmology, with the abstract published in the publication, Investigative Ophthalmology and Visual Science in June 2020, NaV1.7 receptor is present on the cornea and as such, is a viable biological target for treating eye pain. Channel has developed a number of topical ophthalmic formulation |

166

TABLE OF CONTENTS

of CT2000 that are being evaluated for ophthalmic efficacy and toxicology in two in vivo models, which will be followed by a POC trial in patients. Channel expects the human POC trials for this ophthalmic formulation of CT2000 to start in the second quarter 2025.

| • | Develop CT3000 for the treatment of post-surgical pain.Based on its pre-clinical profile, and the target validation, if approved by the FDA, Channel believes that CT3000 has the potential to become a drug for treatment of acute post operative surgical pain for knee and shoulder surgery where nerve blocks are appropriate, potentially delivering meaningful clinical benefits over the currently available standard of care. |

| • | Advance the development of CC8464 towards FDA approval for treating EM and iSFN.Based on its pre-clinical profile, the target validation and trends seen with other NaV1.7 blockers in clinical studies, if approved by the FDA, Channel believes that CC8464 has the potential to become a drug for treatment of EM and iSFN patients, potentially delivering meaningful clinical benefits over the currently available standard of care. |

| • | Leverage Channel’s differentiated research and discovery approach to expand its pipeline.Channel plans to build a pipeline of potential pain blockers acting against sodium-channels related to NaV1.7. Pain modulation is complex, and a multitude of physiological mechanisms are